The patch mimics natural infection kinetics using sustained-release microneedles implanted in a patient's dermal barrier. The controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, which ultimately boosts a vaccine's effectiveness, according to the company.

Originally conceived at the Massachusetts Institute of Technology and Tufts University, the technology utilizes the unique qualities of silk proteins and mechanisms involved in immune system activation.

Cell-free technique could enable on-demand vaccine production
A new cell-free synthetic biology technique that increases the volume of membrane components in the manufacture of conjugate vaccines can significantly...

Debiopharm launches competition for single dose COVID-19 mRNA vaccine
Debiopharm has announced a global challenge in an effort to develop a single-dose messenger RNA (mRNA) COVID-19 vaccine.

Variant-resistant COVID-19 vaccines could be effective, cheap to make
Researchers have collaborated to create a new COVID-19 vaccine platform containing antigens against the fusion protein of the SARS-CoV-2 virus that could...

Aegis Life starts Entos DNA COVID-19 vaccine clinical trial
Aegis Life, subsidiary of Entos Pharmaceuticals, has begun a phase I/II clinical trial of Entos' Covigenix VAX-001, a DNA COVID-19 vaccine.

Vaxess receives $2M from the U.S. government
Vaxess Technologies has been awarded a grant from the National Science Foundation and a subcontract from the Defense Advanced Research Projects Agency,...